Invention Grant
- Patent Title: Antibodies to CD40 with enhanced agonist activity
-
Application No.: US15195098Application Date: 2016-06-28
-
Publication No.: US10479838B2Publication Date: 2019-11-19
- Inventor: Jeffrey V. Ravetch , Rony Dahan , Bryan C. Barnhart , Brigitte Devaux , Aaron P. Yamniuk , Shannon L. Okada , Brenda L. Stevens
- Applicant: The Rockefeller University , BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton US NY New York
- Assignee: Bristol-Myers Squibb Company,The Rockefeller University
- Current Assignee: Bristol-Myers Squibb Company,The Rockefeller University
- Current Assignee Address: US NJ Princeton US NY New York
- Agency: Fox Rothschild LLP
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/28 ; A61K39/00
Abstract:
Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for FcγRIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
Public/Granted literature
- US20160376371A1 ANTIBODIES TO CD40 WITH ENHANCED AGONIST ACTIVITY Public/Granted day:2016-12-29
Information query
